Skip to content

Study · Randomized controlled trial · n = 228 · 2024

5 results

Response rates for lumbar spine, total hip, and femoral neck bone mineral density in men treated with abaloparatide: results from the ATOM study.

Dhaliwal R, Kendler D, Saag K, Ing SW, Singer A, Adler RA, Pearman L, Wang Y, Mitlak B

JBMR plus27 Jan 2024Cited by 4 (Europe PMC)

PMID38505522 (opens in a new tab)PMCIDPMC10945712 (opens in a new tab)DOI10.1093/jbmrpl/ziae009 (opens in a new tab)PepBankPUB-38505522
Read at sourcePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In men with osteoporosis, abaloparatide improved lumbar spine, total hip and femoral neck bone mineral density versus placebo.

    In plain wordsIn men with osteoporosis, abaloparatide improved bone density at the lower spine, total hip and femoral neck more than placebo.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    IncreaseLumbar spine, total hip and femoral neck bone mineral density
    Study

    n = 228

    Comparator
    Placebo
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    80 μg · subcutaneous · 12 monthsAs given in this study (human).

    Source sentences

    Summary
    Abaloparatide significantly improved LS, TH, and FN BMD when compared with placebo.
    Summary
    In conclusion, use of abaloparatide compared with placebo for 12 mo resulted in significant and rapid improvements in BMD in men with osteoporosis from the ATOM study.
    1 context sentence
    Summary · context
    In the Abaloparatide for the Treatment of Men With Osteoporosis (ATOM; NCT03512262) trial, 228 men with primary or hypogonadism-associated osteoporosis were randomized to receive subcutaneous injections of abaloparatide 80 μg or placebo.
  2. 02HumanRandomized controlled trialEfficacy outcome

    At month 3, more men receiving abaloparatide than placebo gained >3% lumbar spine BMD: 61.2% versus 30.9%.

    In plain wordsAt month 3, more men receiving abaloparatide than placebo gained >3% lower spine bone density.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    IncreaseLumbar spine BMD gain above 3% at month three
    Study

    n = 202

    Comparator
    Placebo
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    80 μg · subcutaneous · 3 monthsAs given in this study (human).

    Measurements

    Responders
    61.2%
    abaloparatide, month 3
    Responders
    30.9%
    placebo, month 3

    Source sentences

    Summary
    At month 3, more men treated with abaloparatide than placebo had a > 3% BMD increase at the LS (82/134 [61.2%] vs 21/68 [30.9%], P < .0001).
    1 context sentence
    Summary · context
    In the Abaloparatide for the Treatment of Men With Osteoporosis (ATOM; NCT03512262) trial, 228 men with primary or hypogonadism-associated osteoporosis were randomized to receive subcutaneous injections of abaloparatide 80 μg or placebo.
  3. 03HumanRandomized controlled trialEfficacy outcome

    At month 6, more men receiving abaloparatide than placebo gained >3% BMD at all three sites: 14.8% versus 1.4%.

    In plain wordsAt month 6, more men receiving abaloparatide than placebo gained >3% bone density at all measured sites.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    IncreaseBMD gain above 3% at all sites at month six
    Study

    n = 192

    Comparator
    Placebo
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    80 μg · subcutaneous · 6 monthsAs given in this study (human).

    Measurements

    Responders
    14.8%
    abaloparatide, month 6
    Responders
    1.4%
    placebo, month 6

    Source sentences

    Summary
    There were significantly more men with a BMD gain of >3% at all 3 anatomical sites in the abaloparatide than placebo group at month 6 (18/122 [14.8%] vs 1/70 [1.4%], P = .002) and at month 12 (38/119 [31.9%] vs 1/66 [1.5%], P < .0001).
    1 context sentence
    Summary · context
    In the Abaloparatide for the Treatment of Men With Osteoporosis (ATOM; NCT03512262) trial, 228 men with primary or hypogonadism-associated osteoporosis were randomized to receive subcutaneous injections of abaloparatide 80 μg or placebo.
  4. 04HumanRandomized controlled trialEfficacy outcome

    At month 12, more men receiving abaloparatide than placebo gained >3% BMD at all three sites: 31.9% versus 1.5%.

    In plain wordsAt month 12, more men receiving abaloparatide than placebo gained >3% bone density at all measured sites.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    IncreaseBMD gain above 3% at all sites at month twelve
    Study

    n = 185

    Comparator
    Placebo
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    80 μg · subcutaneous · 12 monthsAs given in this study (human).

    Measurements

    Responders
    31.9%
    abaloparatide, month 12
    Responders
    1.5%
    placebo, month 12

    Source sentences

    Summary
    There were significantly more men with a BMD gain of >3% at all 3 anatomical sites in the abaloparatide than placebo group at month 6 (18/122 [14.8%] vs 1/70 [1.4%], P = .002) and at month 12 (38/119 [31.9%] vs 1/66 [1.5%], P < .0001).
    1 context sentence
    Summary · context
    In the Abaloparatide for the Treatment of Men With Osteoporosis (ATOM; NCT03512262) trial, 228 men with primary or hypogonadism-associated osteoporosis were randomized to receive subcutaneous injections of abaloparatide 80 μg or placebo.
  5. 05HumanRandomized controlled trialEfficacy outcome

    In men with osteoporosis, abaloparatide improved T-score category to low BMD or normal more often than placebo.

    In plain wordsIn men with osteoporosis, abaloparatide improved the bone density category more often than placebo.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    IncreaseT-score category improvement
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    80 μg · subcutaneous · 12 monthsAs given in this study (human).

    Source sentences

    Summary
    A greater proportion of men treated with abaloparatide had an improvement in T-score category from osteoporosis to low BMD or normal when compared with placebo.
    2 context sentences
    Summary · context
    In this prespecified analysis, the proportion of men with a percent change from baseline of >0%, >3%, and > 6% in BMD at the LS, TH, and FN at 3, 6, and 12 mo and/or a shift in T-score category (based on LS and TH T-scores) at 12 mo was compared between the abaloparatide and placebo groups in ATOM.
    Summary · context
    In the Abaloparatide for the Treatment of Men With Osteoporosis (ATOM; NCT03512262) trial, 228 men with primary or hypogonadism-associated osteoporosis were randomized to receive subcutaneous injections of abaloparatide 80 μg or placebo.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:25 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.